EyePoint (EYPT) Depreciation & Amortization (CF) (2010 - 2026)
EyePoint (EYPT) reported Depreciation & Amortization (CF) of $636000.0 for Q1 2026, up 27.97% on a YoY basis from $497000.0 in Q1 2025, and up 30.06% sequentially from $489000.0 in Q4 2025.
EyePoint (EYPT) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
EyePoint (EYPT) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $636000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 27.97% year-over-year to $636000.0; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (up 29.12% YoY), and the FY2025 full-year result was $2.3 million, up 49.94% from the prior year.
- Depreciation & Amortization (CF) grew to $636000.0 in Q1 2026, from $489000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $636000.0 in Q1 2026 to a low of $81000.0 in Q1 2022.
- A 5-year average of $302117.6 and a median of $303000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) decreased 13.85% in 2023 and surged 316.96% in 2024, its largest moves.
- Tracing EYPT's Depreciation & Amortization (CF) over 5 years: stood at $130000.0 in 2022, then fell by 13.85% to $112000.0 in 2023, then soared by 316.96% to $467000.0 in 2024, then grew by 4.71% to $489000.0 in 2025, then surged by 30.06% to $636000.0 in 2026.
- Business Quant data shows EYPT's Depreciation & Amortization (CF) at $636000.0 in Q1 2026, $489000.0 in Q4 2025, and $576000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 | 636,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 636,000.00 |
| Mar 31, 2026 | 636,000.00 |
| Dec 31, 2025 | 489,000.00 |
| Dec 31, 2025 | 489,000.00 |
| Sep 30, 2025 | 576,000.00 |
| Sep 30, 2025 | 576,000.00 |
| Jun 30, 2025 | 538,000.00 |
| Jun 30, 2025 | 538,000.00 |
| Mar 31, 2025 | 497,000.00 |
| Mar 31, 2025 | 497,000.00 |
| Dec 31, 2024 | 467,000.00 |
| Dec 31, 2024 | 467,000.00 |
| Sep 30, 2024 | 408,000.00 |
| Sep 30, 2024 | 408,000.00 |
| Jun 30, 2024 | 362,000.00 |
| Jun 30, 2024 | 362,000.00 |
| Mar 31, 2024 | 303,000.00 |
| Mar 31, 2024 | 303,000.00 |
| Dec 31, 2023 | 112,000.00 |
| Dec 31, 2023 | 112,000.00 |